The biopharma Axsome Therapeutics (Nasdaq:AXSM) has won FDA approval for Auvelity (dextromethorphan HBr-bupropion HCl) extended-release tablets for treating major depressive disorder (MDD) in adults. Auvelity is the only rapid-acting oral medicine for MDD with labeling describing statistically significant antidepressant efficacy at one week. Clinical trial data also show that the drug maintains efficacy at week…